Day: March 2, 2023

Delivered Record Quarterly and Annual Net Investment Income of $18.4 and $59.8 Million, Respectively Increased Core Leverage Ratio of Portfolio to 97% Grew Investment Portfolio to Record $1.1 Billion Conference Call Today, Thursday, March 2 at 6:00 p.m. ET WOODSIDE, Calif., March 02, 2023 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 HighlightsTotal investment income of $36.8 million Net investment income of $18.4 million, or $0.45 per share Net asset value of $14.22 per share Dollar-weighted annualized yield on debt investments of...

Company to Host Conference Call Today, March 2, at 4:30pm ET BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2022 and provides a business update. Q4 2022 and 2022 Corporate Highlights:   DN-TNF Platform Highlights (XPro™ and INB03™):Consolidating the Mild Cognitive Impairment (MCI) Phase 2 trial into the Mild Alzheimer’s Disease Phase 2 study which will become a single Phase 2 AD trial. The combined trials should improve our ability to demonstrate a clinical benefit in patients receiving XPro™, accelerate enrollment, and reduce costs. Including patients...

Reports double-digit growth in Connected Television (CTV) revenue and Active Customers; Disruptive product launches position AdTheorent for future growth NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — AdTheorent Holding Company, Inc. (Nasdaq: ADTH) (“AdTheorent” or “the Company”), a programmatic digital advertising leader using advanced machine learning technology and privacy-forward solutions to deliver real-world value for advertisers and marketers, today announced fourth quarter and full-year 2022 financial results. “We accomplished many great things in our first year as a public company, such as expanding our technological advantage over competing CTV products, growing CTV revenue by 54%, growing our Active Customer base by 12%, revolutionizing the concept of what a targetable programmatic ‘Audience’ can be with the launch of...

Board of Directors Declared Total Dividends of $0.66 per Share for First Quarter 2023 Base Dividend Increased to $0.41 Per Share, Reflecting Improved Earnings Power of Fidus’ Portfolio EVANSTON, Ill., March 02, 2023 (GLOBE NEWSWIRE) — Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market companies based in the United States, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial HighlightsTotal investment income of $27.5 million Net investment income of $12.5 million, or $0.51 per share Adjusted net investment income of $12.6 million, or $0.51 per share(1) Invested $65.9 million in debt and equity securities, including four new portfolio...

Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective activation, providing initial clinical platform validation Anticipate initiating Phase 2 monotherapy clinical trial for XTX202 in melanoma and renal cell carcinoma in April 2023 Ended 2022 with $120.4 million in cash and cash equivalents; continue to anticipate cash runway into the second quarter of 2024 WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December...

Company Achieves Highest Fiscal Year Revenue in Company History Strong Adoption of New Higher Margin Smoothie Carton Format Following Roll Out in Fourth Quarter of 2022 Full Year 2022 Revenue Increased 37% Year-Over-Year to Record $9.2 Million and Gross Margins Improved Sequentially to 36% in Fourth Quarter of 2022 Company Focused on Replacing Lost Bottle Manufacturer and Increasing Production of New Smoothie Carton Product in Fiscal Year 2023 Company Has Generated More Revenue to Date for First Quarter 2023 Compared to Complete Fourth Quarter of 2022 Company Expects Record Revenue in Fiscal 2023 and Year-over-Year Margin Improvement LOS ANGELES, March 02, 2023 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, is providing...

Second Quarter HighlightsRevenue grows 52% year-over-year to $387.6 million Calculated billings grows 34% year-over-year to $493.8 million Deferred revenue grows 46% year-over-year to $1,111.9 million GAAP net loss of $57.5 million compared to GAAP net loss of $100.4 million on a year-over-year basis Non-GAAP net income of $57.6 million compared to non-GAAP net income of $19.2 million on a year-over-year basisSAN JOSE, Calif., March 02, 2023 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2023, ended January 31, 2023. “We exceeded both our revenue and profitability guidance in Q2, demonstrating the operating leverage inherent in our business model,” said Jay Chaudhry, Chairman and CEO of Zscaler. “Even in this difficult...

MOUNTAIN VIEW, Calif., March 02, 2023 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full-year ended December 31, 2022. Recent HighlightsAchieved total revenue of $12.8 million for the fourth quarter of 2022, representing a 16% increase over the fourth quarter of 2021 Achieved initial implant revenue of $9.8 million for the fourth quarter of 2022, representing a 15% increase over the fourth quarter of 2021 Generated $1.6 million of revenue in the fourth quarter of 2022 from the distribution of DIXI Medical products, marking the first quarter of revenue contributions from the distribution arrangement Completed onboarding all centers participating in the NAUTILUS...

RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™(PGS), today announced its operating and financial results for the fourth quarter and full year 2022. As the Company hosted an Investor Day on Tuesday, February 21, 2023 during which an in-depth review of the business was provided, the Company will not be hosting an earnings conference call in conjunction with this earnings release. Recent HighlightsIn February 2023, unveiled plans for the LUNA™ Surgical System, its next generation digital surgery platform In February 2023, announced the intention to collaborate with KARL STORZ on developing next-generation instrumentation...

– Approximately $71 Million of International Product Sales in 2022 – – Corporate Update Conference Call Today at 4:30 PM ET – NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2022. “In 2022, SIGA had approximately $111 million in revenue including approximately $71 million of international sales. Importantly, we generated revenue from a more diversified customer base compared to previous years,” said Phil Gomez, CEO of SIGA. “The year included the first sale of the intravenous formulation of TPOXX® (“IV TPOXX”) to the U.S. Government, the first sales of oral TPOXX to the U.S. Department of Defense (“DoD”), and the sale of oral TPOXX (tecovirimat)...